Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: A randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial

The Lancet Infectious Diseases

Volumn 15, Issue 2, 2015, Pages 161-171

  Zhong, Nan Shan ^a   Sun, Tieying ^b   Zhuo, Chao ^a   D'Souza, George ^c   Lee, Sang Haak ^d   Lan, Nguyen Huu ^e   Chiang, Chi Huei ^f   Wilson, David ^g   Sun, Fang ^g   Iaconis, Joseph ^g   Melnick, David ^g  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Pham Ngoc Thach Hospital   (Viet Nam)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; POTASSIUM; SODIUM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ASTHMA; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ESCHERICHIA COLI; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAEMOPHILUS INFLUENZAE; HEMOLYTIC ANEMIA; HOSPITAL ADMISSION; HUMAN; HYPOKALEMIA; INDIA; INTENTION TO TREAT ANALYSIS; KLEBSIELLA PNEUMONIAE; LUNG TUBERCULOSIS; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SOUTH KOREA; STREPTOCOCCUS PNEUMONIAE; TAIWAN; TREATMENT DURATION; URINARY TRACT INFECTION; VIET NAM; VOMITING; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; TREATMENT OUTCOME;

EID: 84921321887     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)71018-7     Document Type: Article

References (29)

1. Wunderink RG, Waterer GW Community-acquired pneumonia. N Engl J Med 2014, 370:543-551.
2. Song JH, Thamlikitkul V, Hsueh PR Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents 2011, 38:108-117.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72.
4. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17(suppl 6):E1-59.
5. Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India 2012, 29(suppl 2):S27-S62. for the Pneumonia Guidelines Working Group.
6. He LX Guidelines for the diagnosis and treatment of community-acquired pneumonia: learning and practicing. Zhonghua Jie He He Hu Xi Za Zhi 2006, 29:649-650. (in Chinese).
7. Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006. J Microbiol Immunol Infect 2007, 40:279-283.
8. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 2006, 11(suppl 3):S79-133. Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections.
9. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics AstraZeneca, (accessed July 8, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002252/WC500132586.pdf.
10. Teflaro (ceftaroline fosamil) injection for intravenous (IV) use: US prescribing information Forest Pharmaceuticals, (accessed July 8, 2014). http://www.frx.com/pi/Teflaro_pi.pdf.
11. File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(suppl 3):iii19-iii32.
12. Low DE, File TM, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(suppl 3):iii33-iii44.
13. File TM, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010, 51:1395-1405.
14. Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg 2014, 108:326-337.
15. Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008, 31:107-114.
16. Mendes RE, Mendoza M, Banga Singh KK, et al. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob Agents Chemother 2013, 57:5721-5726.
17. Zhang X, Wang R, Di X, Liu B, Liu Y Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014, 6:134-142.
18. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
19. Miettinen O, Nurminen M Comparative analysis of two rates. Stat Med 1985, 4:213-226.
20. Segev S, Raz R, Rubinstein E, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur J Clin Microbiol Infect Dis 1995, 14:851-855.
21. Yang L, Li H, Sunzel M, Xu P, Edeki T, Li J Pharmacokinetics (PK) and safety of single and multiple intravenous (IV) infusions of ceftaroline fosamil in healthy Chinese subjects. Int J Antimicrob Agents 2013, 42(suppl 2):S78.
22. Sunzel M, Kujacic M Broadhurst H, Li J, Edeki T. Phase I, randomised single- and multiple-dose study of ceftaroline fosamil 600 mg every 12 h (60-min infusion) and every 8 h (120-min infusion). 24th European Congress of Microbiology and Infectious Diseases; Barcelona, Spain; May 10-13, 2014. P-1737.
23. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008, 46:1142-1151.
24. Guidance for industry. Community-acquired bacteriaL pneumonia: developing drugs for treatment (revision 2, January 2014) US Food and Drug Administration Center for Drug Evaluation and Research, (accessed July 8, 2014). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm123686.pdf.
25. Rocephin (ceftriaxone): summary of product characteristics, labelling and package leaflet Roche, (accessed July 8, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Rocephin_30/WC500160113.pdf.
26. Drusano GL What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?. J Antimicrob Chemother 2011, 66(suppl 3):iii61-iii67.
27. Riccobene T, Pushkin R, Jandourek A. Penetration of ceftaroline into epithelial lining fluid in healthy adult subjects. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, USA; Sept 10-13, 2013. A-469.
28. Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 2003, 51:83-91.
29. Rank DR, Friedland HD, Laudano JB Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011, 66(suppl 3):iii53-iii59.